CCCC C4 Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CCCC

Price (delayed)

$3.08

Market cap

$378.92M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.91

Enterprise value

$353.72M

?
Relative Growth: Rel. Growth: 40
Relative Strength: Rel. Strength: 60
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 35
Highlights
C4 Therapeutics's equity has increased by 42% YoY and by 6% QoQ
The EPS has increased by 42% year-on-year and by 17% since the previous quarter
The quick ratio has declined by 40% since the previous quarter but it is up by 8% year-on-year
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CCCC

CCCC stock price

How has the C4 Therapeutics stock price performed over time
Intraday
-6.95%
1 week
-10.72%
1 month
-23%
1 year
18.92%
YTD
61.26%
QTD
-34.05%

Financial performance

How have C4 Therapeutics's revenue and profit performed over time
Revenue
$35.04M
Gross profit
$35.04M
Operating income
-$111.77M
Net income
-$101.42M
Gross margin
100%
Net margin
-289.4%
The operating margin has grown by 12% YoY and by 2.3% from the previous quarter
The company's net margin rose by 11% YoY and by 2.8% QoQ
The operating income has increased by 10% year-on-year
CCCC's net income is up by 9% YoY and by 2.3% QoQ

Price vs fundamentals

How does CCCC's price correlate with its fundamentals

Growth

What is C4 Therapeutics's growth rate over time

Valuation

What is C4 Therapeutics stock price valuation
P/E
N/A
P/B
1.38
P/S
11.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.1
The EPS has increased by 42% year-on-year and by 17% since the previous quarter
C4 Therapeutics's equity has increased by 42% YoY and by 6% QoQ
The price to book (P/B) is 23% higher than the last 4 quarters average of 1.2 but 8% lower than the 5-year quarterly average of 1.6
CCCC's price to sales (P/S) is 34% more than its last 4 quarters average of 9.2 but 12% less than its 5-year quarterly average of 14.0
The company's revenue rose by 2.3% YoY

Efficiency

How efficient is C4 Therapeutics business performance
C4 Therapeutics's ROE has increased by 16% YoY and by 10% from the previous quarter
The return on sales has increased by 11% year-on-year and by 2.8% since the previous quarter
The company's return on assets rose by 7% YoY and by 7% QoQ
C4 Therapeutics's return on invested capital has increased by 7% QoQ and by 5% YoY

Dividends

What is CCCC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CCCC.

Financial health

How did C4 Therapeutics financials performed over time
The quick ratio has declined by 40% since the previous quarter but it is up by 8% year-on-year
The current ratio is down by 39% QoQ but it is up by 8% YoY
The company's debt is 77% lower than its equity
C4 Therapeutics's equity has increased by 42% YoY and by 6% QoQ
CCCC's debt to equity is down by 36% year-on-year and by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.